Orthofix Medical Inc. (OFIX)

Orthofix Medical’s earnings in the second fiscal quarter of 2026 topped expectations on EPS while revenue came in line, with results reported August 5, 2026. EPS was -$0.39 versus the -$0.41 estimate (topped by $0.02) and was down -8.3% from -$0.36 a year ago, while revenue rose 3.8% to about $210.9 million (up from $203.1 million) and was $210.9 million against a $209.3 million estimate (+0.8%, in line). Gross profit was roughly $149.7 million, with gross margin at about 71.0%, and the quarter included an operating loss of around $8.1 million, leaving operating margin at roughly -3.9%. Net loss widened -12.2% to about $15.8 million (from -$14.1 million a year ago). By geography, the U.S. contributed about $170.0 million of revenue (down -1.0% year over year) while International revenue was roughly $40.9 million (up +30.3%), including a component that rose +66.2% to about $13.3 million. The company generated negative operating cash flow of about $6.2 million. Consensus for the next period calls for EPS of $0.11 on revenue of $210.7 million.